Potential Therapeutic Usage of Nanomedicine for Glaucoma Treatment

References

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267. doi:10.1136/bjo.2005.08122416488940
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Aung T, Medeiros FAJJ. The pathophysiology and treatment of glaucoma: a review. Jama. 2014;311(18):1901–1911.24825645
   PubMed Web of Science ®Google Scholar
• Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016;10:189–206. doi:10.2147/OPTH.S8049026869753
   PubMed Web of Science ®Google Scholar
• Schlunck G, Meyer-ter-Vehn T, Klink T, Grehn F. Conjunctival fibrosis following filtering glaucoma surgery. Exp Eye Res. 2016;142:76–82. doi:10.1016/j.exer.2015.03.02126675404
   PubMed Web of Science ®Google Scholar
• Bengtsson B, Heijl A. Lack of visual field improvement after initiation of intraocular pressure reducing treatment in the early manifest glaucoma trial. Invest Ophthalmol Vis Sci. 2016;57(13):5611–5615. doi:10.1167/iovs.16-1938927768797
   PubMed Web of Science ®Google Scholar
• Song YK, Lee CK, Kim J, Hong S, Kim CY, Seong GJ. Instability of 24-hour intraocular pressure fluctuation in healthy young subjects: a prospective, cross-sectional study. BMC Ophthalmol. 2014;14(1):127. doi:10.1186/1471-2415-14-12725370361
   PubMedGoogle Scholar
• Grant WM, Burke JF Jr. Why do some people go blind from glaucoma? Ophthalmology. 1982;89(9):991–998. doi:10.1016/S0161-6420(82)34675-87177577
   PubMed Web of Science ®Google Scholar
• Susanna R, De Moraes CG, Cioffi GA. Ritch RJTvs, technology. Why do people (still) go blind from glaucoma? Trans vision sci technol. 2015;4(2):1.
   PubMed Web of Science ®Google Scholar
• Asiedu K, Dzasimatu SK, Kyei SJCL, Eye A. Clinical subtypes of dry eye in youthful clinical sample in Ghana. Contact Lens Anterior Eye. 2019;42(2):206–211.30337142
   PubMed Web of Science ®Google Scholar
• Smith DM, Simon JK, Baker Jr JR Jr. Applications of nanotechnology for immunology. Nat Rev Immunol. 2013;13(8):592–605. doi:10.1038/nri348823883969
   PubMed Web of Science ®Google Scholar
• Chow EK, Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med. 2013;5(216):216rv214. doi:10.1126/scitranslmed.3005872
   Web of Science ®Google Scholar
• Butcher NJ, Mortimer GM, Minchin RF. Drug delivery: unravelling the stealth effect. Nat Nanotechnol. 2016;11(4):310–311. doi:10.1038/nnano.2016.626878145
   PubMed Web of Science ®Google Scholar
• Bayford R, Rademacher T, Roitt I, Wang SX. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review. Physiol Meas. 2017;38(8):R183–R203. doi:10.1088/1361-6579/aa718228480874
   PubMed Web of Science ®Google Scholar
• Johari B, Kadivar M, Lak S, et al. Osteoblast-seeded bioglass/gelatin nanocomposite: a promising bone substitute in critical-size calvarial defect repair in rat. Int J Artif Organs. 2016;39(10):524–533. doi:10.5301/ijao.500053327901555
   PubMed Web of Science ®Google Scholar
• Samadikuchaksaraei A, Gholipourmalekabadi M, Erfani Ezadyar E, et al. Fabrication and in vivo evaluation of an osteoblast-conditioned nano-hydroxyapatite/gelatin composite scaffold for bone tissue regeneration. J Biomed Mater Res A. 2016;104(8):2001–2010. doi:10.1002/jbm.a.3573127027855
   PubMed Web of Science ®Google Scholar
• Kargozar S, Mozafari M, Hashemian SJ, et al. Osteogenic potential of stem cells-seeded bioactive nanocomposite scaffolds: A comparative study between human mesenchymal stem cells derived from bone, umbilical cord Wharton’s jelly, and adipose tissue. J Biomed Mater Res B Appl Biomater. 2018;106(1):61–72. doi:10.1002/jbm.b.3381427862947
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Leung CK, Crowston JG, et al. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016;2(1):16067. doi:10.1038/nrdp.2016.6727654570
   PubMedGoogle Scholar
• Lee EJ, Han JC, Park DY, Kee C. A neuroglia-based interpretation of glaucomatous neuroretinal rim thinning in the optic nerve head. Prog Retin Eye Res. 2020;100840. doi:10.1016/j.preteyeres.2020.10084031982595
   PubMed Web of Science ®Google Scholar
• Walsh JT, Robbins SL, Savino PJ. Visual Field Loss in a Patient With Optic Disc Cupping. JAMA Ophthalmol. 2019;137(7):844–845. doi:10.1001/jamaophthalmol.2019.117331120527
   PubMed Web of Science ®Google Scholar
• Levkovitch-Verbin H. Optic nerve cupping represents neuronal loss. Ophthalmology. 2020;127(4S):S43–S44. doi:10.1016/j.ophtha.2020.01.02432200825
   PubMedGoogle Scholar
• Chen SJ, Lu P, Zhang WF, Lu JH. High myopia as a risk factor in primary open angle glaucoma. Int J Ophthalmol. 2012;5(6):750–753. doi:10.3980/j.issn.2222-3959.2012.06.1823275912
   PubMed Web of Science ®Google Scholar
• Choquet H, Thai KK, Yin J, et al. A large multi-ethnic genome-wide association study identifies novel genetic loci for intraocular pressure. Nat Commun. 2017;8(1):2108. doi:10.1038/s41467-017-01913-629235454
   PubMedGoogle Scholar
• Johnson M, McLaren JW, Overby DR. Unconventional aqueous humor outflow: A review. Exp Eye Res. 2017;158:94–111. doi:10.1016/j.exer.2016.01.01726850315
   PubMed Web of Science ®Google Scholar
• Ho LTY, Osterwald A, Ruf I, et al. Role of the autotaxin-lysophosphatidic acid axis in glaucoma, aqueous humor drainage and fibrogenic activity. Biochim Biophys Acta Mol Basis Dis. 2020;1866(1):165560. doi:10.1016/j.bbadis.2019.16556031648019
   PubMed Web of Science ®Google Scholar
• Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4(1):52–59. doi:10.2174/187436410100401005221293732
   PubMedGoogle Scholar
• Yan X, Li M, Song Y, et al. Influence of exercise on intraocular pressure, schlemm’s canal, and the trabecular meshwork. Invest Ophthalmol Vis Sci. 2016;57(11):4733–4739. doi:10.1167/iovs.16-1947527607419
   PubMed Web of Science ®Google Scholar
• Vrabec JP, Levin LA. The neurobiology of cell death in glaucoma. Eye (Lond). 2007;21(Suppl 1):S11–S14. doi:10.1038/sj.eye.670288018157171
   PubMedGoogle Scholar
• Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711–1720. doi:10.1016/S0140-6736(04)16257-015158634
   PubMed Web of Science ®Google Scholar
• Bessero AC, Clarke PG. Neuroprotection for optic nerve disorders. Curr Opin Neurol. 2010;23(1):10–15. doi:10.1097/WCO.0b013e328334446119915465
   PubMed Web of Science ®Google Scholar
• Fang JH, Wang XH, Xu ZR, Jiang FG. Neuroprotective effects of bis(7)-tacrine against glutamate-induced retinal ganglion cells damage. BMC Neurosci. 2010;11(1):31. doi:10.1186/1471-2202-11-3120199668
   PubMedGoogle Scholar
• Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res. 2006;25(5):490–513. doi:10.1016/j.preteyeres.2006.07.00316962364
   PubMed Web of Science ®Google Scholar
• Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. J Glaucoma. 2009;18(2):93–100. doi:10.1097/IJG.0b013e318181284f19225343
   PubMed Web of Science ®Google Scholar
• Group, C.N.T.G.S. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126(4):487–497. doi:10.1016/S0002-9394(98)00223-29780093
   PubMed Web of Science ®Google Scholar
• Fedorchak MV, Conner IP, Schuman JS, Cugini A, Little SR. Long term glaucoma drug delivery using a topically retained gel/microsphere eye drop. Sci Rep. 2017;7(1):8639. doi:10.1038/s41598-017-09379-828819134
   PubMedGoogle Scholar
• Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014;5(1):30–43. doi:10.1177/204062231351128624381726
   PubMedGoogle Scholar
• Hejkal TW, Camras CB. Prostaglandin analogs in the treatment of glaucoma. Semin Ophthalmol. 1999;14(3):114–123. doi:10.3109/0882053990906146410790575
   PubMedGoogle Scholar
• Camras C, Toris C. Advances in glaucoma management: risk factors, diagnostic tools, therapies and the role of prostaglandin analogs. Foreword. Surv Ophthalmol. 2008;53(Suppl1):S1–S2. doi:10.1016/j.survophthal.2008.08.01319038617
   PubMedGoogle Scholar
• Alizadeh R, Akil H, Tan J, Law SK, Caprioli J. Trabeculectomy outcomes after glaucoma drainage device surgery. J Glaucoma. 2018;27(2):133–139. doi:10.1097/IJG.000000000000084929239864
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993;83(5):711–716. doi:10.2105/AJPH.83.5.7118484454
   PubMed Web of Science ®Google Scholar
• Loch C, Zakelj S, Kristl A, et al. Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes. Eur J Pharm Sci. 2012;47(1):131–138. doi:10.1016/j.ejps.2012.05.00722659372
   PubMed Web of Science ®Google Scholar
• Scruggs J, Wallace T, Hanna C. Route of absorption of drug and ointment after application to the eye. Ann Ophthalmol. 1978;10(3):267–271.655537
   PubMedGoogle Scholar
• Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479–1488. doi:10.1021/js980259410189253
   PubMed Web of Science ®Google Scholar
• Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131–1135. doi:10.1016/j.addr.2006.07.02717097758
   PubMed Web of Science ®Google Scholar
• Bito LZ, Baroody RA. The penetration of exogenous prostaglandin and arachidonic acid into, and their distribution within, the mammalian eye. Curr Eye Res. 1981;1(11):659–669. doi:10.3109/027136881090018707346237
   PubMed Web of Science ®Google Scholar
• Wei G, Xu H, Ding PT, SM L, Zheng JM. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release. 2002;83(1):65–74. doi:10.1016/S0168-3659(02)00175-X12220839
   PubMed Web of Science ®Google Scholar
• Hamalainen KM, Kananen K, Auriola S, Kontturi K, Urtti A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci. 1997;38(3):627–634.9071216
   PubMed Web of Science ®Google Scholar
• Lavik E, Kuehn MH, Kwon YH. Novel drug delivery systems for glaucoma. Eye (Lond). 2011;25(5):578–586. doi:10.1038/eye.2011.8221475311
   PubMed Web of Science ®Google Scholar
• Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47–64. doi:10.5497/wjp.v2.i2.4725590022
   PubMedGoogle Scholar
• Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348–360. doi:10.1208/s12248-010-9183-320437123
   PubMed Web of Science ®Google Scholar
• Wei G, Ding PT, Zheng JM, Lu WY. Pharmacokinetics of timolol in aqueous humor sampled by microdialysis after topical administration of thermosetting gels. Biomed Chromatogr. 2006;20(1):67–71. doi:10.1002/bmc.52915954162
   PubMed Web of Science ®Google Scholar
• Cardigos J, Ferreira Q, Crisostomo S, et al. Nanotechnology-ocular devices for glaucoma treatment: a literature review. Curr Eye Res. 2019;44(2):111–117. doi:10.1080/02713683.2018.153621830309248
   PubMed Web of Science ®Google Scholar
• Patel S, Pasquale LR. Glaucoma drainage devices: a review of the past, present, and future. Semin Ophthalmol. 2010;25(5–6):265–270. doi:10.3109/08820538.2010.51884021091010
   PubMed Web of Science ®Google Scholar
• Alvarado JA, Hollander DA, Juster RP, Lee LC. Ahmed valve implantation with adjunctive mitomycin C and 5-fluorouracil: long-term outcomes. Am J Ophthalmol. 2008;146(2):276–284. doi:10.1016/j.ajo.2008.04.00818538300
   PubMed Web of Science ®Google Scholar
• Ponnusamy T, Yu H, John VT, Ayyala RS, Blake DA. A novel antiproliferative drug coating for glaucoma drainage devices. J Glaucoma. 2014;23(8):526–534. doi:10.1097/IJG.0b013e318294869b23632409
   PubMed Web of Science ®Google Scholar
• Sommer A. Collaborative normal-tension glaucoma study. Am J Ophthalmol. 1999;128(6):776–777. doi:10.1016/S0002-9394(99)00369-410612525
   PubMed Web of Science ®Google Scholar
• Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. Low-pressure glaucoma study g. a randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011;151(4):671–681. doi:10.1016/j.ajo.2010.09.02621257146
   PubMed Web of Science ®Google Scholar
• Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx. 2005;2(1):99–107. doi:10.1602/neurorx.2.1.9915717061
   PubMedGoogle Scholar
• Li X, Hu D, Dang Y, et al. Nano Mapper: an Internet knowledge mapping system for nanotechnology development. J Nanopart Res. 2009;11(3):529–552. doi:10.1007/s11051-008-9491-z21170121
   PubMed Web of Science ®Google Scholar
• Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24(10):1211–1217. doi:10.1038/nbt1006-121117033654
   PubMed Web of Science ®Google Scholar
• Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanotechnology in ophthalmology. Can J Ophthalmol. 2010;45(5):457–476. doi:10.3129/i10-09020871642
   PubMed Web of Science ®Google Scholar
• Bucolo C, Drago F, Salomone S. Ocular drug delivery: a clue from nanotechnology. Front Pharmacol. 2012;3:188. doi:10.3389/fphar.2012.0018823125835
   PubMed Web of Science ®Google Scholar
• Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine in ophthalmology: the new frontier. Am J Ophthalmol. 2010;150(2):144–162. (). doi:10.1016/j.ajo.2010.03.01920670739
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3–4):144–151. doi:10.1016/j.drudis.2007.10.02118275912
   PubMed Web of Science ®Google Scholar
• Lu H, Wang J, Wang T, Zhong J, Bao Y, Hao H. Recent Progress on nanostructures for drug delivery applications. J Nanomater. 2016;2016:5762431. doi:10.1155/2016/5762431
   Web of Science ®Google Scholar
• Kim HJ, Zhang K, Moore L, Ho D. Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release. ACS Nano. 2014;8(3):2998–3005. doi:10.1021/nn500296824506583
   PubMed Web of Science ®Google Scholar
• Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for treating glaucoma. Crit Rev Ther Drug Carrier Syst. 2014;31(5):365–405. doi:10.1615/CritRevTherDrugCarrierSyst.201401012325271557
   PubMed Web of Science ®Google Scholar
• Pita-Thomas DW, Goldberg JL. Nanotechnology and glaucoma: little particles for a big disease. Curr Opin Ophthalmol. 2013;24(2):130–135. doi:10.1097/ICU.0b013e32835cfe9223287105
   PubMed Web of Science ®Google Scholar
• Gaafar PM, Abdallah OY, Farid RM, Abdelkader H. Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone. J Liposome Res. 2014;24(3):204–215. doi:10.3109/08982104.2014.88185024484536
   PubMed Web of Science ®Google Scholar
• Janagam DR, Wu L, Lowe TL. Nanoparticles for drug delivery to the anterior segment of the eye. Adv Drug Deliv Rev. 2017;122:31–64. doi:10.1016/j.addr.2017.04.00128392306
   PubMed Web of Science ®Google Scholar
• Puglia C, Offerta A, Tirendi GG, et al. Design of solid lipid nanoparticles for caffeine topical administration. Drug Deliv. 2016;23(1):36–40. doi:10.3109/10717544.2014.90301124735249
   PubMed Web of Science ®Google Scholar
• Kim M, Park JH, Jeong H, et al. An Evaluation of the in vivo Safety of Nonporous Silica Nanoparticles: ocular Topical Administration versus Oral Administration. Sci Rep. 2017;7(1):8238. doi:10.1038/s41598-017-08843-928811672
   PubMedGoogle Scholar
• Natarajan JV, Darwitan A, Barathi VA, et al. Sustained drug release in nanomedicine: a long-acting nanocarrier-based formulation for glaucoma. ACS Nano. 2014;8(1):419–429. doi:10.1021/nn404602424392729
   PubMed Web of Science ®Google Scholar
• Salatin S, Yari Khosroushahi A. Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles. J Cell Mol Med. 2017;21(9):1668–1686. doi:10.1111/jcmm.1311028244656
   PubMed Web of Science ®Google Scholar
• Nagai N, Ogata F, Otake H, Nakazawa Y, Kawasaki N. Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles. Int J Nanomedicine. 2019;14:1213–1227. doi:10.2147/IJN.S19668130863055
   PubMed Web of Science ®Google Scholar
• Zhu S, Gong L, Li Y, Xu H, Gu Z, Zhao Y. Safety Assessment of Nanomaterials to Eyes: an Important but Neglected Issue. Adv Sci. 2019;6(16):1802289. doi:10.1002/advs.201802289
   Web of Science ®Google Scholar
• Prow TW. Toxicity of nanomaterials to the eye. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(4):317–333. doi:10.1002/wnan.6520077524
   PubMed Web of Science ®Google Scholar
• Kim KT, Zaikova T, Hutchison JE, Tanguay RL. Gold nanoparticles disrupt zebrafish eye development and pigmentation. Toxicol Sci. 2013;133(2):275–288. doi:10.1093/toxsci/kft08123549158
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297–315.17717971
   PubMed Web of Science ®Google Scholar
• Mastrobattista E, Koning GA, van Bloois L, Filipe AC, Jiskoot W, Storm G. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem. 2002;277(30):27135–27143. doi:10.1074/jbc.M20042920012021269
   PubMed Web of Science ®Google Scholar
• Monem AS, Ali FM, Ismail MW. Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. Int J Pharm. 2000;198(1):29–38. doi:10.1016/S0378-5173(99)00348-810722948
   PubMed Web of Science ®Google Scholar
• Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523–580. doi:10.1615/CritRevTherDrugCarrierSyst.v26.i6.1020402623
   PubMed Web of Science ®Google Scholar
• Jain RL, Shastri JP. Study of ocular drug delivery system using drug-loaded liposomes. Int J Pharm Investig. 2011;1(1):35–41. doi:10.4103/2230-973X.76727
   PubMedGoogle Scholar
• Yu S, Wang QM, Wang X, et al. Liposome incorporated ion sensitive in situ gels for opthalmic delivery of timolol maleate. Int J Pharm. 2015;480(1–2):128–136. doi:10.1016/j.ijpharm.2015.01.03225615987
   PubMed Web of Science ®Google Scholar
• Law SL, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J Control Release. 2000;63(1–2):135–140. doi:10.1016/S0168-3659(99)00192-310640587
   PubMed Web of Science ®Google Scholar
• Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech. 2007;8(1):1. doi:10.1208/pt080100117408209
   PubMed Web of Science ®Google Scholar
• Velpandian T, Gupta SK, Gupta YK, Biswas NR, Agarwal HC. Ocular drug targeting by liposomes and their corneal interactions. J Microencapsul. 1999;16(2):243–250. doi:10.1080/02652049928921110080117
   PubMed Web of Science ®Google Scholar
• Mehanna MM, Elmaradny HA, Samaha MW. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment. Drug Dev Ind Pharm. 2010;36(1):108–118. doi:10.3109/0363904090309975119656004
   PubMed Web of Science ®Google Scholar
• Sasaki H, Karasawa K, Hironaka K, Tahara K, Tozuka Y, Takeuchi H. Retinal drug delivery using eyedrop preparations of poly-L-lysine-modified liposomes. Eur J Pharm Biopharm. 2013;83(3):364–369. doi:10.1016/j.ejpb.2012.10.01423153668
   PubMed Web of Science ®Google Scholar
• Ruel-Gariepy E, Leclair G, Hildgen P, Gupta A, Leroux JC. Thermosensitive chitosan-based hydrogel containing liposomes for the delivery of hydrophilic molecules. J Control Release. 2002;82(2–3):373–383. doi:10.1016/S0168-3659(02)00146-312175750
   PubMed Web of Science ®Google Scholar
• Tan G, Yu S, Pan H, et al. Bioadhesive chitosan-loaded liposomes: A more efficient and higher permeable ocular delivery platform for timolol maleate. Int J Biol Macromol. 2017;94(Pt A):355–363. doi:10.1016/j.ijbiomac.2016.10.03527760378
   PubMedGoogle Scholar
• Natarajan JV, Ang M, Darwitan A, Chattopadhyay S, Wong TT, Venkatraman SS. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomedicine. 2012;7:123–131. doi:10.2147/IJN.S2546822275828
   PubMed Web of Science ®Google Scholar
• Li T, Tachibana K, Kuroki M, Kuroki M. Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice–initial results. Radiology. 2003;229(2):423–428. doi:10.1148/radiol.229202050014512507
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Tachibana K, Hiraoka K, et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther. 2002;9(6):372–380. doi:10.1038/sj.gt.330167811960313
   PubMed Web of Science ®Google Scholar
• Lindner JR. Microbubbles in medical imaging: current applications and future directions. Nat Rev Drug Discov. 2004;3(6):527–532. doi:10.1038/nrd141715173842
   PubMed Web of Science ®Google Scholar
• Mizoue T, Horibe T, Maruyama K, et al. Targetability and intracellular delivery of anti-BCG antibody-modified, pH-sensitive fusogenic immunoliposomes to tumor cells. Int J Pharm. 2002;237(1–2):129–137. doi:10.1016/S0378-5173(02)00044-311955811
   PubMedGoogle Scholar
• Sugano M, Negishi Y, Endo-Takahashi Y, et al. Gene delivery system involving Bubble liposomes and ultrasound for the efficient in vivo delivery of genes into mouse tongue tissue. Int J Pharm. 2012;422(1–2):332–337. doi:10.1016/j.ijpharm.2011.11.00122100513
   PubMedGoogle Scholar
• Kouchak M, Bahmandar R, Bavarsad N, Farrahi F. Ocular Dorzolamide Nanoliposomes for Prolonged IOP Reduction: in-Vitro and in-vivo Evaluation in Rabbits. Iran J Pharm Res. 2016;15(1):205–212.
   PubMed Web of Science ®Google Scholar
• Kouchak M, Malekahmadi M, Bavarsad N, Saki Malehi A, Andishmand L. Dorzolamide nanoliposome as a long action ophthalmic delivery system in open angle glaucoma and ocular hypertension patients. Drug Dev Ind Pharm. 2018;44(8):1239–1242. doi:10.1080/03639045.2017.138619628956449
   PubMed Web of Science ®Google Scholar
• Fahmy HM, Saad E, Sabra NM, El-Gohary AA, Mohamed FF, Gaber MH. Treatment merits of Latanoprost/Thymoquinone - Encapsulated liposome for glaucomatus rabbits. Int J Pharm. 2018;548(1):597–608. doi:10.1016/j.ijpharm.2018.07.01229997042
   PubMedGoogle Scholar
• Wong TT, Novack GD, Natarajan JV, Ho CL, Htoon HM, Venkatraman SS. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. Drug Deliv Transl Res. 2014;4(4):303–309. doi:10.1007/s13346-014-0196-925787063
   PubMed Web of Science ®Google Scholar
• Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems–an overview. Adv Colloid Interface Sci. 2012;183–184:46–54. doi:10.1016/j.cis.2012.08.002
   PubMed Web of Science ®Google Scholar
• Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28(5):473–493. doi:10.1081/DDC-12000344512098838
   PubMed Web of Science ®Google Scholar
• Kaur IP, Aggarwal D, Singh H, Kakkar S. Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1467–1472. doi:10.1007/s00417-010-1383-020437246
   PubMed Web of Science ®Google Scholar
• Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm. 2005;290(1–2):155–159. doi:10.1016/j.ijpharm.2004.10.02615664141
   PubMedGoogle Scholar
• Aggarwal D, Pal D, Mitra AK, Kaur IP. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm. 2007;338(1–2):21–26. doi:10.1016/j.ijpharm.2007.01.01917300885
   PubMedGoogle Scholar
• Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269(1):1–14. doi:10.1016/j.ijpharm.2003.09.01614698571
   PubMed Web of Science ®Google Scholar
• Liu G, Molas M, Grossmann GA, et al. Biological properties of poly-L-lysine-DNA complexes generated by cooperative binding of the polycation. J Biol Chem. 2001;276(37):34379–34387. doi:10.1074/jbc.M10525020011438546
   PubMed Web of Science ®Google Scholar
• Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release. 2009;136(1):2–13. doi:10.1016/j.jconrel.2008.12.01819331856
   PubMed Web of Science ®Google Scholar
• Jung HJ, Abou-Jaoude M, Carbia BE, Plummer C, Chauhan A. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. J Control Release. 2013;165(1):82–89. doi:10.1016/j.jconrel.2012.10.01023123188
   PubMed Web of Science ®Google Scholar
• Harmia T, Speiser P, Kreuter J. A solid colloidal drug delivery system for the eye: encapsulation of pilocarpin in nanoparticles. J Microencapsul. 1986;3(1):3–12. doi:10.3109/026520486090495803508173
   PubMedGoogle Scholar
• Rathod LV, Kapadia R, Sawant KK. A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: in vitro, in vivo and stability studies. Mater Sci Eng C Mater Biol Appl. 2017;71:529–540. doi:10.1016/j.msec.2016.10.01727987741
   PubMed Web of Science ®Google Scholar
• Singh J, Chhabra G, Pathak K. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. Ex vivo evaluation and pharmacodynamic study. Drug Dev Ind Pharm. 2014;40(9):1223–1232. doi:10.3109/03639045.2013.81406123837522
   PubMed Web of Science ®Google Scholar
• Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci. 2009;38(3):185–196. doi:10.1016/j.ejps.2009.07.00819646528
   PubMed Web of Science ®Google Scholar
• Spataro G, Malecaze F, Turrin CO, et al. Designing dendrimers for ocular drug delivery. Eur J Med Chem. 2010;45(1):326–334. doi:10.1016/j.ejmech.2009.10.01719889480
   PubMed Web of Science ®Google Scholar
• Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release. 2005;102(1):23–38. doi:10.1016/j.jconrel.2004.09.01515653131
   PubMed Web of Science ®Google Scholar
• Yang H, Leffler CT. Hybrid dendrimer hydrogel/poly(lactic-co-glycolic acid) nanoparticle platform: an advanced vehicle for topical delivery of antiglaucoma drugs and a likely solution to improving compliance and adherence in glaucoma management. J Ocul Pharmacol Ther. 2013;29(2):166–172. doi:10.1089/jop.2012.019723249385
   PubMed Web of Science ®Google Scholar
• Bravo-Osuna I, Vicario-de-la-Torre M, Andres-Guerrero V, et al. Novel Water-Soluble Mucoadhesive Carbosilane Dendrimers for Ocular Administration. Mol Pharm. 2016;13(9):2966–2976. doi:10.1021/acs.molpharmaceut.6b0018227149661
   PubMedGoogle Scholar
• Chen MC, Gupta M, Cheung KC. Alginate-based microfluidic system for tumor spheroid formation and anticancer agent screening. Biomed Microdevices. 2010;12(4):647–654. doi:10.1007/s10544-010-9417-220237849
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Jani R. A novel formulation of an ophthalmic beta-adrenoceptor antagonist. J Parenter Sci Technol. 1992;46(2):51–53.1588458
   PubMedGoogle Scholar
• Weinreb RN, Caldwell DR, Goode SM, et al. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution. Am J Ophthalmol. 1990;110(2):189–192. doi:10.1016/S0002-9394(14)76990-92198812
   PubMed Web of Science ®Google Scholar
• Ranpise NS, Kulkarni NS, Mair PD, Ranade AN. Improvement of water solubility and in vitro dissolution rate of aceclofenac by complexation with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin. Pharm Dev Technol. 2010;15(1):64–70. doi:10.3109/1083745090300216519505225
   PubMed Web of Science ®Google Scholar
• Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57(11):1595–1639. doi:10.1016/j.addr.2005.07.00516198021
   PubMed Web of Science ®Google Scholar
• Laza-Knoerr AL, Gref R, Couvreur P. Cyclodextrins for drug delivery. J Drug Target. 2010;18(9):645–656. doi:10.3109/1061186100362255220497090
   PubMed Web of Science ®Google Scholar
• Granero GE, Longhi MR. Promising complexes of acetazolamide for topical ocular administration. Expert Opin Drug Deliv. 2010;7(8):943–953. doi:10.1517/17425247.2010.49753620565335
   PubMed Web of Science ®Google Scholar
• Jansook P, Stefansson E, Thorsteinsdottir M, et al. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm. 2010;76(2):208–214. doi:10.1016/j.ejpb.2010.07.00520637867
   PubMed Web of Science ®Google Scholar
• Wang F, Bao X, Fang A, et al. Nanoliposome-Encapsulated Brinzolamide-hydropropyl-beta-cyclodextrin Inclusion Complex: A Potential Therapeutic Ocular Drug-Delivery System. Front Pharmacol. 2018;9:91. doi:10.3389/fphar.2018.0009129487529
   PubMed Web of Science ®Google Scholar
• Rodriguez-Aller M, Guinchard S, Guillarme D, et al. New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance. Eur J Pharm Biopharm. 2015;95(Pt B):203–214. doi:10.1016/j.ejpb.2015.04.03225960331
   PubMedGoogle Scholar
• Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295–309. doi:10.2147/ijn.s59518990939
   PubMed Web of Science ®Google Scholar
• Wu W, Li J, Wu L, et al. Ophthalmic delivery of brinzolamide by liquid crystalline nanoparticles: in vitro and in vivo evaluation. AAPS PharmSciTech. 2013;14(3):1063–1071. doi:10.1208/s12249-013-9997-223813437
   PubMed Web of Science ®Google Scholar
• Tuomela A, Liu P, Puranen J, et al. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm. 2014;467(1–2):34–41. doi:10.1016/j.ijpharm.2014.03.04824680962
   PubMed Web of Science ®Google Scholar
• Orasugh JT, Sarkar G, Saha NR, et al. Effect of cellulose nanocrystals on the performance of drug loaded in situ gelling thermo-responsive ophthalmic formulations. Int J Biol Macromol. 2019;124:235–245. doi:10.1016/j.ijbiomac.2018.11.21730481535
   PubMed Web of Science ®Google Scholar
• Ikuta Y, Aoyagi S, Tanaka Y, et al. Creation of nano eye-drops and effective drug delivery to the interior of the eye. Sci Rep. 2017;7(1):44229. doi:10.1038/srep4422928290486
   PubMedGoogle Scholar
• Mochalin VN, Shenderova O, Ho D, Gogotsi Y. The properties and applications of nanodiamonds. Nat Nanotechnol. 2011;7(1):11–23. doi:10.1038/nnano.2011.20922179567
   PubMed Web of Science ®Google Scholar
• Lloyd AW, Faragher RG, Denyer SP. Ocular biomaterials and implants. Biomaterials. 2001;22(8):769–785. doi:10.1016/S0142-9612(00)00237-411246945
   PubMed Web of Science ®Google Scholar
• Cocero MJMÁ, Mattea F, Varona S, Varona S. Encapsulation and co-precipitation processes with supercritical fluids: fundamentals and applications. J Supercrit Fluid. 2009;47(3):546–555. doi:10.1016/j.supflu.2008.08.015
   Web of Science ®Google Scholar
• Choi SW, Kim J. Therapeutic Contact Lenses with Polymeric Vehicles for Ocular Drug Delivery: A Review. Materials (Basel). 2018;11(7):1125. doi:10.3390/ma11071125
   PubMed Web of Science ®Google Scholar
• Peng CC, Burke MT, Carbia BE, Plummer C, Chauhan A. Extended drug delivery by contact lenses for glaucoma therapy. J Control Release. 2012;162(1):152–158. doi:10.1016/j.jconrel.2012.06.01722721817
   PubMed Web of Science ®Google Scholar
• Jung HJ, Chauhan A. Temperature sensitive contact lenses for triggered ophthalmic drug delivery. Biomaterials. 2012;33(7):2289–2300. doi:10.1016/j.biomaterials.2011.10.07622182750
   PubMed Web of Science ®Google Scholar
• Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J Drug Target. 2010;18(4):292–302. doi:10.3109/1061186090345002319943753
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov. 2012;11(7):541–559. doi:10.1038/nrd374522699774
   PubMed Web of Science ®Google Scholar
• Liang SY, Lee GA, Shields D. Self-tonometry in glaucoma management–past, present and future. Surv Ophthalmol. 2009;54(4):450–462. doi:10.1016/j.survophthal.2009.04.00619539833
   PubMed Web of Science ®Google Scholar
• Kim J, Kim M, Lee MS, et al. Wearable smart sensor systems integrated on soft contact lenses for wireless ocular diagnostics. Nat Commun. 2017;8(1):14997. doi:10.1038/ncomms1499728447604
   PubMedGoogle Scholar
• Leonardi M, Pitchon EM, Bertsch A, Renaud P, Mermoud A. Wireless contact lens sensor for intraocular pressure monitoring: assessment on enucleated pig eyes. Acta Ophthalmol. 2009;87(4):433–437. doi:10.1111/j.1755-3768.2008.01404.x19016660
   PubMed Web of Science ®Google Scholar
• Dunbar GE, Shen BY, Aref AA. The Sensimed Triggerfish contact lens sensor: efficacy, safety, and patient perspectives. Clin Ophthalmol. 2017;11:875–882. doi:10.2147/OPTH.S10970828507427
   PubMed Web of Science ®Google Scholar
• Enders P, Cursiefen C. Device profile of the EYEMATE-IO system for intraocular pressure monitoring: overview of its safety and efficacy. Expert Rev Med Devices. 2020;1–7. doi:10.1080/17434440.2020.1761788
   Web of Science ®Google Scholar
• Salim S, Du H, Wan J. Comparison of intraocular pressure measurements and assessment of intraobserver and interobserver reproducibility with the portable ICare rebound tonometer and Goldmann applanation tonometer in glaucoma patients. J Glaucoma. 2013;22(4):325–329. doi:10.1097/IJG.0b013e318237caa223542696
   PubMed Web of Science ®Google Scholar
• Peng HT, Shek PN. Novel wound sealants: biomaterials and applications. Expert Rev Med Devices. 2010;7(5):639–659. doi:10.1586/erd.10.4020822387
   PubMed Web of Science ®Google Scholar
• Spierer O, O’Brien TP. Endothelial keratoplasty combined with cataract surgery or alone using polyethylene glycol hydrogel sealant for closure of corneal incisions. J Cataract Refract Surg. 2015;41(3):492–496. doi:10.1016/j.jcrs.2015.02.00225804578
   PubMed Web of Science ®Google Scholar
• Masket S, Hovanesian JA, Levenson J, et al. Hydrogel sealant versus sutures to prevent fluid egress after cataract surgery. J Cataract Refract Surg. 2014;40(12):2057–2066. doi:10.1016/j.jcrs.2014.03.03425465686
   PubMed Web of Science ®Google Scholar
• Barliya T, Sandalon S, Ofri R, Livnat T, Weinberger D. Transcleral approach for closing retinal tears using DuraSeal hydrogel sealant. Indian J Ophthalmol. 2018;66(2):238–243. doi:10.4103/ijo.IJO_758_1729380766
   PubMed Web of Science ®Google Scholar
• Preethi G, Prashanth K. Design and evaluation of controlled-release ocular inserts of brimonidine-tartrate and timolol maleate. Int J Pharm Pharm Sci. 2017;9(1):79–82.
   Google Scholar
• Perera SA, Ting DS, Nongpiur ME, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol. 2016;10:757–764. doi:10.2147/OPTH.S10218127175058
   PubMed Web of Science ®Google Scholar
• A Phase 2 study evaluating safety and efficacy of the latanoprost punctal plug delivery system (L-PPDS) in subjects with ocular hypertension (OH) or open-angle glaucoma (OAG). 2019 https://iovs.arvojournals.org/article.aspx?articleid=2358808. Accessed 611, 2020.
   Google Scholar
• Park AJ, Eliassi-Rad B, Desai MA. Ptosis after glaucoma surgery. Clin Ophthalmol. 2017;11:1483–1489. doi:10.2147/OPTH.S13456228860697
   PubMed Web of Science ®Google Scholar
• Pan T, Brown JD, Ziaie B. An artificial nano-drainage implant (ANDI) for glaucoma treatment. Conf Proc IEEE Eng Med Biol Soc. 2006;1:3174–3177.
   Google Scholar
• Paschalis EI, Chodosh J, Sperling RA, Salvador-Culla B, Dohlman C. A novel implantable glaucoma valve using ferrofluid. PLoS One. 2013;8(6):e67404. doi:10.1371/journal.pone.006740423840691
   PubMed Web of Science ®Google Scholar
• Maleki T, Chitnis G, Park JH, Cantor LB, Ziaie B. Biodegradable microfabricated plug-filters for glaucoma drainage devices. IEEE Trans Biomed Eng. 2012;59(6):1507–1513. doi:10.1109/TBME.2011.217903122186928
   PubMed Web of Science ®Google Scholar
• Harake RS, Ding Y, Brown JD, Design PT. Fabrication, and In Vitro Testing of an Anti-biofouling Glaucoma Micro-shunt. Ann Biomed Eng. 2015;43(10):2394–2405. doi:10.1007/s10439-015-1309-425821113
   PubMed Web of Science ®Google Scholar
• Abu-Hassan DW, Acott TS, Kelley MJ. The Trabecular Meshwork: A Basic Review of Form and Function. J Ocul Biol. 2014;2(1).
   PubMedGoogle Scholar
• Gong H, Swain D. The histopathological changes in the trabecular outflow pathway and their possible effects on aqueous outflow in eyes with primary open-angle glaucoma. Glaucoma res clin adv. 2016;17–40.
   Google Scholar
• Castro A, Du Y. Trabecular Meshwork Regeneration - A Potential Treatment for Glaucoma. Curr Ophthalmol Rep. 2019;7(2):80–88. doi:10.1007/s40135-019-00203-231316866
   PubMedGoogle Scholar
• Hu Y, Tan HB, Wang XM, Rong H, Cui HP, Cui H. Bone marrow mesenchymal stem cells protect against retinal ganglion cell loss in aged rats with glaucoma. Clin Interv Aging. 2013;8:1467–1470. doi:10.2147/CIA.S4735024204132
   PubMed Web of Science ®Google Scholar
• Mobaraki M, Abbasi R, Omidian Vandchali S, Ghaffari M, Moztarzadeh F, Mozafari M. Corneal Repair and Regeneration: current Concepts and Future Directions. Front Bioeng Biotechnol. 2019;7:135. doi:10.3389/fbioe.2019.0013531245365
   PubMed Web of Science ®Google Scholar
• Alvarado J, Murphy C, Polansky J, Juster R. Age-related changes in trabecular meshwork cellularity. Invest Ophthalmol Vis Sci. 1981;21(5):714–727.7298275
   PubMed Web of Science ®Google Scholar
• Grierson I, Howes RC. Age-related depletion of the cell population in the human trabecular meshwork. Eye (Lond). 1987;1(Pt 2):204–210.3653434
   PubMedGoogle Scholar
• Du Y, Yun H, Yang E, Schuman J. Science v. stem cells from trabecular meshwork home to TM tissue in vivo. Investophthalmol visual sci. 2013;54(2):1450–1459.
   PubMed Web of Science ®Google Scholar
• Snider EJ, Kubelick KP, Tweed K, et al. Improving stem cell delivery to the trabecular meshwork using magnetic nanoparticles. Sci Rep. 2018;8(1):12251. doi:10.1038/s41598-018-30834-730115953
   PubMedGoogle Scholar
• Dillinger AE, Guter M, Froemel F, et al. Intracameral delivery of layer‐by‐layer coated siRNA nanoparticles for glaucoma therapy.Small. 2018;14(50):1803239.
   Web of Science ®Google Scholar
• Dautriche CN, Szymanski D, Kerr M, et al. A biomimetic Schlemm’s canal inner wall: A model to study outflow physiology, glaucoma pathology and high-throughput drug screening. Biomaterials. 2015;65:86–92.26142779
   PubMed Web of Science ®Google Scholar
• Dautriche CN, Xie Y, Sharfstein S. Walking through trabecular meshwork biology: toward engineering design of outflow physiology. Biotechnol adv. 2014;32(5):971–983.24806891
   PubMed Web of Science ®Google Scholar
• Torrejon KY, Papke EL, Halman JR, et al. Bioengineered glaucomatous 3D human trabecular meshwork as an in vitro disease model. Biotechnol bioeng. 2016;113(6):1357–1368.26615056
   PubMed Web of Science ®Google Scholar
• Waduthanthri KD, He Y, Montemagno C, Cetinel S. An injectable peptide hydrogel for reconstruction of the human trabecular meshwork. Acta biomater. 2019;100:244–254.31557533
   PubMed Web of Science ®Google Scholar
• Ward M, Khoobehi A, Lavik E, Langer R, Young M. Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres. J pharm sci. 2007;96(3):558–568.17177208
   PubMed Web of Science ®Google Scholar
• Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. 2007.
   Google Scholar
• Checa-Casalengua P, Jiang C, Bravo-Osuna I, et al. Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J Control Rel. 2011;156(1):92–100.
   PubMed Web of Science ®Google Scholar
• García-Caballero C, Prieto-Calvo E, Checa-Casalengua P, et al. Six month delivery of GDNF from PLGA/vitamin E biodegradable microspheres after intravitreal injection in rabbits0. Eur J Pharm Sci. 2017;103:19–26.28259830
   PubMed Web of Science ®Google Scholar
• Nkansah MK, Tzeng SY, Holdt AM, Lavik EBJB. bioengineering. Poly (lactic‐co‐glycolic acid) nanospheres and microspheres for short‐and long‐term delivery of bioactive ciliary neurotrophic factor. Biotechnol bioeng. 2008;100(5):1010–1019.18431801
   PubMed Web of Science ®Google Scholar
• Eastlake K, Wang W, Jayaram H, et al. Phenotypic and functional characterization of muller glia isolated from induced pluripotent stem cell-derived retinal organoids: improvement of retinal ganglion cell function upon transplantation. Stem Cells Transl Med. 2019;8(8):775–784. doi:10.1002/sctm.18-026331037833
   PubMed Web of Science ®Google Scholar
• Ooto S, Akagi T, Kageyama R, et al. Potential for neural regeneration after neurotoxic injury in the adult mammalian retina. Proc Natl Acad Sci U S A. 2004;101(37):13654–13659. doi:10.1073/pnas.040212910115353594
   PubMed Web of Science ®Google Scholar
• Lawrence JM, Singhal S, Bhatia B, et al. MIO-M1 cells and similar muller glial cell lines derived from adult human retina exhibit neural stem cell characteristics. Stem Cells. 2007;25(8):2033–2043. doi:10.1634/stemcells.2006-072417525239
   PubMed Web of Science ®Google Scholar